Prevention and Treatment of Cancer-Related Infections, Version 2.2016
Prevention and Treatment of Cancer-Related Infections, Version 2.2016
复制标题
DOI：
10.6004/jnccn.2016.0093
复制
发表时间：
2016-07-01
影响因子：
13.4
通讯作者：
Smith, Courtney
中科院分区：
文献类型：
--
作者：
Baden, Lindsey Robert;Swaminathan, Sankar;Smith, Courtney
传染病是癌症患者发病和死亡的重要原因。 《NCCN 癌症相关感染预防和治疗临床实践指南》（NCCN 指南）描述了癌症患者易感的主要病原体，重点关注主要常见感染和机会性感染的预防、诊断和治疗。指南的这一部分重点介绍了有关抗真菌和抗病毒预防的部分。在过去几年中，抗真菌和抗病毒预防建议有所扩大。提出了治疗真菌感染的新药物并结合治疗药物监测。乙型肝炎的抗病毒预防以及丙型肝炎和艾滋病毒的管理考虑因素已得到进一步发展。
Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.